Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration
Κύριοι συγγραφείς: | Chakravarthy, U, Harding, S, Rogers, C, Downes, S, Lotery, A, Wordsworth, S, Reeves, B |
---|---|
Μορφή: | Journal article |
Έκδοση: |
2012
|
Παρόμοια τεκμήρια
Παρόμοια τεκμήρια
-
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.
ανά: Chakravarthy, U, κ.ά.
Έκδοση: (2012) -
Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial
ανά: Chakravarthy, U, κ.ά.
Έκδοση: (2012) -
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.
ανά: Dakin, H, κ.ά.
Έκδοση: (2014) -
Quality of fixation in eyes with neovascular age-related macular degeneration treated with ranibizumab.
ανά: Sivaprasad, S, κ.ά.
Έκδοση: (2011) -
Treat-And-extend bevacizumab for neovascular age-related macular degeneration: The importance of baseline characteristics
ανά: Rush, R, κ.ά.
Έκδοση: (2014)